Last €89.59 EUR
Change Today +0.76 / 0.86%
Volume 3.3K
As of 3:19 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Open
€89.02
Previous Close
€88.83
Day High
€89.93
Day Low
€88.55
52 Week High
11/25/14 - €90.53
52 Week Low
04/15/14 - €48.55
Market Cap
71.6B
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
798.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; strategic collaboration with Sutro Biopharma, Inc. to discover and develop antibodies and antibody drug conjugates; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

5,100 Employees
Last Reported Date: 02/13/14
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.3M
President and Chief Operating Officer
Total Annual Compensation: $666.7K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $645.8K
President of Global Hematology and Oncology
Total Annual Compensation: $753.3K
President of Research and Early Development ...
Total Annual Compensation: $645.8K
Compensation as of Fiscal Year 2013.

celgene corp (CG3) Key Developments

Triphase Accelerator Corporation Announces Expanded Collaboration with Celgene Corporation

Triphase Accelerator Corp. announced an expansion of its strategic collaboration with Celgene Corporation. The supplemental agreement adds a Phase I development program that will explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma (GBM), an aggressive malignant primary brain tumor. Under the supplemental agreement, Triphase will receive additional development funds through a cost sharing arrangement with Celgene. Triphase will control product development and retain all commercial rights to marizomib until and unless Celgene exercises its option to acquire the product from Triphase for an undisclosed payment, at which time Triphase would then be eligible to receive regulatory and sales milestone payments.

Celgene Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Year of 2014

Celgene Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $1,982.20 million against $1,674.4 million a year ago. Operating income was $646.6 million against $455.6 million a year ago. Income before income taxes was $577.5 million against $442.0 million a year ago. Net income was $508.5 million against $372.5 million a year ago. Diluted earnings per share were $0.61 against $0.43 a year ago. Net income, adjusted was $805.6 million or $0.97 per diluted share against $669.5 million or $0.78 per diluted share a year ago. Operating cash flow was $901 million. Earnings growth was entirely driven by operating income. For the nine months, the company reported total revenues of $5,584.9 million against $4,738.0 million a year ago. Operating income was $1,767.3 million against $1,483.1 million a year ago. Income before income taxes was $1,616.6 million against $1,448.2 million a year ago. Net income was $1,386.0 million against $1,235.5 million a year ago. Diluted earnings per share were $1.66 against $1.43 a year ago. Net income, adjusted was $2,258.4 million or $2.70 per diluted share against $1,914.1 million or $2.22 per diluted share a year ago. The company revised earnings guidance for the year 2014. For the year, the company expects net income to be in the range of $1,987.5 million to $2,070.3 million. Net income, adjusted to be in the range of $3,047.8 million to $3,089.5 million. Total revenue expected to exceed $7,600 million, an increase of approximately 17% year-over-year. Adjusted operating margin now expected to be slightly over 50%. GAAP operating margin expected to be approximately 33%. Adjusted diluted EPS raised to a range of $3.65 to $3.70 from the previous range of $3.60 to $3.65, an increase of approximately 23% year-over-year. GAAP diluted EPS is expected to be in the range of $2.38 to $2.48 from the previous range of $2.46 to $2.55. Amortization of acquired intangible assets to be in the range of $258.3 million.

Sutro Biopharma and Celgene Corporation Enter into Multi-Year Strategic Collaboration and Option to Acquire Agreement

Sutro Biopharma entered into a strategic collaboration and option agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development, and manufacture of best-in-class biotherapeutics. The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, such as PD-1 and PD-L1, as well as novel targets, using Sutro's cell-free biologics development platforms, Xpress CF(TM) and Xpress CF+(TM). During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms. Under terms of the agreement, Sutro will receive upfront payments totaling $95 million, which includes an equity investment. Sutro may also receive up to an additional $90 million during the initial research term, including payments for manufacturing-related and productivity milestones. Celgene has the option to extend the collaboration beyond the initial research term in exchange for an additional payment. Across all product candidates Sutro is eligible to receive more than $1 billion in total payments, upon achievement of clinical and regulatory milestones for product candidates and royalties on product sales resulting from the collaboration. During the collaboration, Sutro will be responsible for discovery and early pre-clinical development of all collaboration multispecific antibodies and ADCs, as well as the manufacturing of pre-clinical product candidates. The collaboration also contemplates a clinical and commercial supply agreement between Sutro and Celgene for collaboration products. Celgene may assume responsibility for global development and commercialization and will have worldwide rights to all collaboration products, with the exception of certain collaboration products for which Sutro retains U.S. development and commercialization rights, in the event Celgene does not exercise its option to acquire Sutro. For product candidates not licensed to Celgene under the collaboration, Sutro retains worldwide rights, in the event Celgene does not exercise its option to acquire Sutro.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €89.59 EUR +0.76

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $304.92 USD -0.48
Bristol-Myers Squibb Co $58.86 USD +0.34
Eli Lilly & Co $67.32 USD +0.47
Regeneron Pharmaceuticals Inc $415.84 USD +2.84
Shire PLC 4,513 GBp +45.00
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 58.4x
Price/Sales 12.1x
Price/Book 13.1x
Price/Cash Flow 47.6x
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.